Burn Clinical Trial - Intron A for the Treatment of Hypertrophic Scar

Status Withdrawn

Clinical Trial Summary

This study assesses the intervention with antifibrotic agents, specifically interferon (IFN) to reduce the magnitude and duration of hypertrophic scar. Burn patients with hypertrophic scar are randomly assigned to either an intervention IFN group or a placebo control group by subcutaneous injection three times a week. Patients are assessed using cutometer, mexameter, standardized photography, urinalysis, blood work, tissue biopsies and the Vancouver Burn Scar Assessment (VBSA) which rates selected HTS based on color, vascularity, height, pliability, itchiness and pain sensitivity. Once on treatment patients are assessed monthly for the six month treatment period.

Clinical Trial Description

Burn patients being followed and treated in the Outpatient Burn Clinic with large areas of HTS are approached to participate in the study. Patients who agree to participate and who have signed an informed consent are entered into the trial.

Pre-treatment evaluation and monthly examinations include:

- standardized photographs of scar

- scar volume

- Vancouver Burn Scar Assessment (VBSA)

- blood work (TGF-beta, histamine)

- urine collection (histamine)

- 6mm punch biopsy of HTS and adjacent normal skin (every two months)

Patients are randomized to received with placebo or Intron A 1x106 IU a day for 7 days, then 3x106 IU 3 SC, three times a week for 23 weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00686478
Study type	Interventional
Source	University of Alberta
Contact
Status	Withdrawn
Phase	Phase 3

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01302457` - Oral Care Study on Burn Patients	N/A
Completed	`NCT02729259` - H2O VR for Burns 2015	N/A
Completed	`NCT01965340` - Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission	N/A
Withdrawn	`NCT01225107` - Effect of Cranberry Extract on Infections in Burn Patients	N/A
Completed	`NCT01983280` - The Effect of Healing Touch on Sleep Patterns of Pediatric Burn Patients	N/A
Completed	`NCT00591448` - Study in the Use of Virtual Reality as an Adjunct to Pain Control in Burn Patients	N/A
Active, not recruiting	`NCT02083900` - Use of Banana Leaf Dressing on Donor Site Wounds	Phase 2
Completed	`NCT00242970` - Hypertrophic Scarring After Facial Burn	Phase 2
Completed	`NCT00585325` - Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes	N/A
Terminated	`NCT00591162` - Bone Disease in Severely Burned Children	Phase 2/Phase 3
Terminated	`NCT02452255` - Fenofibrate and Propranolol in Burn Patients	Phase 2/Phase 3
Completed	`NCT03183622` - A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial	N/A
Completed	`NCT02427659` - VR High Tech Pain Control Burn Wound Care	N/A
Not yet recruiting	`NCT00253279` - Alterations in Protein Synthesis Rates of Burn Patients Measured Over Time Using PET Scans	Phase 1
Completed	`NCT04516148` - A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting	Phase 4
Withdrawn	`NCT02029261` - Observational Study of Insulin Resistance and Muscle Wasting After Burn Injury
Completed	`NCT00993889` - Virtual Reality Analgesia During Pediatric Physical Therapy	N/A
Terminated	`NCT01062191` - Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl	N/A
Completed	`NCT02394873` - A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound	Phase 1
Completed	`NCT00239668` - Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors